Andrew Hirsch lines up a chunk of equity in his new job as C4 spells out development plans in IPO
Andrew Hirsch’s first job as the newly-minted CEO of C4 Therapeutics was already fully spelled out ahead of his arrival.
On Thursday, the biotech jumped into the queue of biotechs angling for a slice of the billions flowing through Nasdaq and into life sciences.
Less than 3 months after a large syndicate jumped into a $170 million crossover raise for C4, and just 2 days after publicly tapping the longtime biotech exec to take the reins, the protein degradation outfit has penciled in a $100 million goal in the IPO. But in this market, that’s a threshold outline that could point to a much larger sum.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.